Silverback Therapeutics Inc. lifted the shades on its secretive operation just enough to reveal an extension of its series A round, previously cited only in SEC filings, to $47.5 million. The financing was led by existing investor Orbimed with participation from new investors Celgene Corp. and Alexandria Venture Investments.